| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Cefazedone exerts its bactericidal activity by binding to and inactivating penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are essential enzymes involved in the final stages of bacterial cell wall assembly and in remodeling the cell wall during bacterial growth and division. Inactivation of PBPs interferes with the cross-linking of peptidoglycan chains, which is crucial for maintaining the strength and rigidity of the bacterial cell wall. This leads to weakening of the bacterial cell wall, ultimately resulting in cell lysis and bacterial death. Cefazedone's antibacterial effect is not affected by β-lactamase production.
|
|---|---|
| ln Vitro |
Cefazedone shows antibacterial activity against a broad range of Gram-positive bacteria including Staphylococcus aureus, Streptococcus pneumoniae, and Enterococcus faecalis, as well as Gram-negative bacteria such as Escherichia coli, Klebsiella spp., Haemophilus influenzae, and Klebsiella pneumoniae. In vitro MIC values are strain-specific; against Escherichia coli, the MIC range is 0.125-4 μg/ml (MIC50 0.25 μg/ml, MIC90 0.5 μg/ml). Against Enterococcus faecalis, MIC ranges from 4-64 μg/ml (MIC50 16 μg/ml, MIC90 32 μg/ml). Against oxacillin-resistant Staphylococcus aureus, MIC ranges from 8-64 μg/ml (MIC50 16 μg/ml, MIC90 64 μg/ml). For clinical isolates from community-acquired pneumonia, MIC is 0.25-1 mg/L. No definitive IC50/EC50 data are available as it is a time-dependent antibiotic; the key PK/PD parameter is the time that free drug concentration exceeds the MIC (fT>MIC).
|
| ln Vivo |
Cefazedone has been studied in vivo in animal models, including beagle dogs, where it is administered via intravenous infusion. In these studies, the intravenous infusion dose was 32 mg/kg over a 20-minute infusion period. There was no obvious pharmacokinetic interaction when cefazedone was combined with etimicin. Clinically, for the treatment of community-acquired pneumonia, adult intravenous infusion regimens involve 2 g every 12 hours as a 30-minute infusion. The mean fT>MIC achieved with this regimen is 55.45±8.12%, which needs to reach 40-60% of the dosing interval to ensure efficacy.
|
| Enzyme Assay |
Cefazedone's activity is assessed using standard in vitro microbiological susceptibility testing methods. The broth dilution method is commonly employed, using a gradient of 0.125-1024 μg/ml. The assay measures the minimum inhibitory concentration (MIC) required to inhibit bacterial growth. As a time-dependent antibiotic, the key parameter evaluated is the time that free drug concentration exceeds the MIC (fT>MIC). The compound's binding to penicillin-binding proteins (PBPs) can be studied using competitive binding assays with radiolabeled penicillin.
|
| Cell Assay |
Cellular assays for cefazedone are conducted using standard microbiological techniques with bacterial cultures. The compound's antibacterial activity is evaluated by determining the minimum inhibitory concentration (MIC) against various bacterial strains using broth microdilution or agar dilution methods. Bacterial growth inhibition is assessed by measuring optical density or by counting colony-forming units. The antibacterial effect is evaluated against both Gram-positive and Gram-negative organisms. Cefazedone's activity is not affected by β-lactamase production.
|
| Animal Protocol |
In vivo animal model experiments for cefazedone have been conducted in beagle dogs to evaluate its pharmacokinetic profile and potential drug interactions. The compound is administered via intravenous infusion at a dose of 32 mg/kg over a 20-minute period. Plasma samples are collected at various time points to measure drug concentrations and assess pharmacokinetic parameters. These studies have shown that there is no obvious pharmacokinetic interaction when cefazedone is combined with etimicin. Such studies are essential for understanding the compound's in vivo behavior and optimizing dosing regimens.
|
| ADME/Pharmacokinetics |
Cefazedone exhibits a high protein binding rate of 93-96%, with a free drug fraction of only 4-7%. Following adult intravenous infusion of 2 g every 12 hours (30-minute infusion), the steady-state peak concentration reaches approximately 175.22±36.28 mg/L, with an AUC0-∞ of 280.51±68.17 mg·h/L. The mean fT>MIC is 55.45±8.12%, which meets the required 40-60% of the dosing interval to ensure efficacy. The compound is a time-dependent antibiotic, meaning its antibacterial efficacy is primarily determined by the duration of time that drug concentrations exceed the MIC.
|
| Toxicity/Toxicokinetics |
Cefazedone is generally well-tolerated in clinical settings, with a safety profile consistent with other first-generation cephalosporins. As a β-lactam antibiotic, common adverse effects may include gastrointestinal disturbances, hypersensitivity reactions (particularly in patients with penicillin allergy), and local reactions at the injection site. The compound is intended for research use only and not for human therapeutic applications.
|
| References | |
| Additional Infomation |
Cefazedone is a first-generation cephalosporin antibiotic with a [(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl group and a [(3,5-dichloro-4-oxopyridin-1(4H)-yl)acetamido] side group at positions 3 and 7, respectively. It is an antibacterial drug. Cefazedone belongs to the cephalosporin class, semi-synthetic derivatives, thiadiazoles, carboxylic acids, and 4-pyridones. Cefazedone is a semi-synthetic first-generation cephalosporin with antibacterial activity. Cefazedone binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the final stages of bacterial cell wall assembly and in remodeling the cell wall during bacterial growth and division. Inactivation of penicillin-binding proteins (PBPs) interferes with the cross-linking of peptidoglycan chains, which is crucial for maintaining the strength and rigidity of the bacterial cell wall. This leads to weakening of the bacterial cell wall, ultimately resulting in cell lysis.
Cefazedone (CAS# 56187-47-4) is a first-generation cephalosporin antibiotic also known by the aliases Refosporen and Cefazedonum. It is a time-dependent antibiotic with activity against both Gram-positive and Gram-negative bacteria. The compound is supplied as an off-white to light yellow solid powder with a molecular weight of 548.428 and a purity of ≥98%. Cefazedone is intended for research use only and is not approved for human therapeutic use. It is commonly used in studies of bacterial infections, antibiotic susceptibility testing, and pharmacokinetic research. |
| Molecular Formula |
C18H15CL2N5O5S3
|
|---|---|
| Molecular Weight |
548.428
|
| Exact Mass |
546.961
|
| CAS # |
56187-47-4
|
| Related CAS # |
63521-15-3 (salt);56187-47-4;
|
| PubChem CID |
71736
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.8±0.1 g/cm3
|
| Index of Refraction |
1.761
|
| LogP |
0.92
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
33
|
| Complexity |
984
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC1=NN=C(S1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)CN4C=C(C(=O)C(=C4)Cl)Cl)SC2)C(=O)O
|
| InChi Key |
VTLCNEGVSVJLDN-MLGOLLRUSA-N
|
| InChi Code |
InChI=1S/C18H15Cl2N5O5S3/c1-7-22-23-18(33-7)32-6-8-5-31-16-12(15(28)25(16)13(8)17(29)30)21-11(26)4-24-2-9(19)14(27)10(20)3-24/h2-3,12,16H,4-6H2,1H3,(H,21,26)(H,29,30)/t12-,16-/m1/s1
|
| Chemical Name |
(6R,7R)-7-[[2-(3,5-dichloro-4-oxopyridin-1-yl)acetyl]amino]-3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
|
| Synonyms |
Refosporen, Cefazedonum; Cefazedone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~227.92 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.79 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.79 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.79 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8234 mL | 9.1169 mL | 18.2339 mL | |
| 5 mM | 0.3647 mL | 1.8234 mL | 3.6468 mL | |
| 10 mM | 0.1823 mL | 0.9117 mL | 1.8234 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
